Ethinyl estradiol / etonogestrel

NuvaRing is a combined etonogestrel/ethinyl estradiol vaginal contraceptive for females of reproductive age, including postpubertal adolescents. It is not indicated before menarche or after menopause. This reference uses the current Organon NuvaRing label; generic equivalents require package verification. Nexplanon is a progestin implant, and Annovera is a different ring with different ingredients/reuse instructions. Neither regimen may be substituted here.

Correct continuous use and timely replacement determine effectiveness. The label’s pregnancy rates describe selected clinical trials, not a guarantee for every user; trials excluded BMI ≥30 kg/m². NuvaRing does not protect against HIV or other STIs. Discuss condoms and appropriate prevention separately from pregnancy protection.

Compress and insert one ring vaginally; its precise position is not critical. Keep it continuously for 21 days, remove on the same weekday/time, then insert a NEW ring exactly seven days later even if bleeding continues. Regularly check that it remains present, including around intercourse. It is not an annual reusable ring.

Without hormonal use in the prior cycle: start on menstrual day 1; starting on days 2–5 requires a male-condom barrier backup for seven days. From another correctly used CHC, switch no later than the day after its usual hormone-free interval. From a POP, start the day after the last pill; from an implant/IUS, start on removal day; from injection, when the next injection is due. These progestin-only switches require seven days of backup. First-trimester completed abortion/miscarriage may start within five days without backup; later starts need the label initiation instructions. Second-trimester and postpartum timing require separate risk review.

If out for less than three hours, rinse with cool/lukewarm water and reinsert promptly. The label directs the following after more than three continuous hours; for an unknown interval, consider pregnancy and test before a new ring. Contact a clinician promptly after an error and recent intercourse to discuss pregnancy risk and emergency contraception; do not combine different algorithms yourself.

Replace a broken/disconnected ring with a new one; breakage can cause injury/discomfort or expulsion but does not release a larger hormone dose. Diaphragms, cervical caps, and internal/female condoms are not recommended as backup because the ring can interfere with placement. Tampons do not alter hormone absorption. Prolonged/continuous use protocols outside the labeled cycle require a separate clinician plan.

CDC 2024 permits CHC initiation whenever reasonably certain the patient is not pregnant, with seven-day backup when started more than five days after menstrual bleeding began; this differs from the label’s day 2–5 backup rule. CDC also provides its own delayed-ring algorithm. These are separately attributed clinical guidance, not a rewriting of the product label. Agree on one appropriate plan with the clinician.

Do not use with high arterial/venous thrombotic risk: smoking over age 35; current/prior DVT or PE; cerebrovascular/coronary disease; thrombogenic valve/rhythm disease; hypercoagulopathy; uncontrolled hypertension; diabetes with vascular disease; focal-neurologic headache or migraine aura; or any migraine over age 35. Other formal contraindications include liver disease or benign/malignant liver tumors, unexplained uterine bleeding, pregnancy, current/prior breast cancer, ingredient hypersensitivity, and ombitasvir/paritaprevir/ritonavir with or without dasabuvir.

Smoking increases serious cardiovascular-event risk with combined hormonal contraception, and risk increases with age and cigarette quantity. NuvaRing must not be used by women over age 35 who smoke. Assess smoking and vascular risk before starting and throughout use.

Commonly reported effects include vaginitis/discharge/discomfort, headache or migraine, mood changes, nausea, breast tenderness, bleeding changes, and ring-related discomfort/expulsion. Serious vascular/allergic events and device injury occur. Suspected overdose may cause nausea or withdrawal bleeding; remove all rings and obtain clinical advice. A broken ring does not deliver an increased hormone dose.

CYP3A4-inducing drugs/herbs—including rifampin/rifabutin, carbamazepine, phenytoin, some other antiseizure drugs, bosentan, griseofulvin, aprepitant, and St John’s wort—can cause breakthrough bleeding or contraceptive failure. Use an alternative nonhormonal method or suitable backup during exposure and for 28 days afterward. HIV/HCV drugs have variable effects, so consult each exact drug label. Standard-dose oral amoxicillin/doxycycline did not affect hormone concentrations in the cited studies; do not generalize enzyme-inducer precautions to all antibiotics.

Strong/moderate CYP3A4 inhibitors and vaginal miconazole can increase hormone exposure. CHCs can lower lamotrigine levels and worsen seizure control, while increasing some substrates including cyclosporine, tizanidine, and theophylline; coordinate monitoring and adjustments. Thyroid replacement may need adjustment due to binding-globulin changes. The contraindicated ombitasvir/paritaprevir/ritonavir regimen requires stopping NuvaRing before treatment; the label allows restarting approximately two weeks after completion. Other HCV regimens, including glecaprevir/pibrentasvir, require exact-product review for ALT risk.

Stop if pregnancy is confirmed; it is contraindicated because contraception has no purpose during established pregnancy. Low-dose CHC early-exposure studies have not shown an increased malformation risk, but are not an indication to continue. The label starts no earlier than four weeks after delivery in nonbreastfeeding users, with seven-day backup and consideration of ovulation/pregnancy; also no earlier than four weeks after second-trimester loss. It advises avoiding use during breastfeeding until weaning where possible because milk production can decrease.

CDC 2024 contraindicates CHCs before postpartum day 21; later eligibility depends on breastfeeding and VTE risks. Breastfeeding users generally can use CHCs after day 42 (MEC 2), differing from label advice to wait until weaning. This is a clinician assessment of eligibility, milk supply, and alternatives, not permission for every postpartum user to start.

Efficacy is expected to be comparable in postpubertal adolescents under 18; premenarche and postmenopausal use are not indicated. Renal pharmacokinetics has not been studied, and no renal dose-adjustment scheme is established. Hepatic impairment can alter steroid metabolism; liver disease/tumors are contraindications, with cessation for relevant dysfunction or jaundice. Pregnancy prevention needs individual medical-eligibility review rather than extrapolated organ-dose adjustments.

Combined hormones suppress gonadotropins and primarily inhibit ovulation; cervical-mucus and endometrial changes also contribute. A ring in place cannot provide STI protection through this mechanism.

Etonogestrel and ethinyl estradiol are absorbed systemically; etonogestrel vaginal bioavailability is approximately 100%. Both undergo hepatic metabolism, with CYP3A4 important for etonogestrel and interaction risk. Hormones/metabolites are eliminated through urine, bile, and feces. Vaginal delivery does not avoid thrombosis or hepatic-enzyme interactions.

Measure BP before initiation and reassess smoking, vascular history, migraine, liver disease, breast cancer, interactions, and pregnancy possibility. The label recommends a yearly healthcare visit including BP; review major symptom changes sooner. CDC does not require routine pelvic examination or broad laboratory screening to initiate CHCs in healthy patients; known medical problems may require targeted assessment.

Record insertion/removal dates, check ring presence, and use a new ring each cycle. Explain label error/backup instructions and seek prompt advice after mistakes or intercourse when protection may be reduced. Report clot symptoms, severe headache/vision change, jaundice, allergy, serious depression, or vaginal injury immediately. Explain no STI protection, interaction backup, postpartum restrictions, and correct disposal. Do not use multiple rings or confuse this ring with a reusable or implant product.

Organon NuvaRing is a flexible transparent, colorless-to-almost-colorless non-biodegradable ring, 54 mm outer diameter and 4 mm cross-section, without natural rubber latex. Each contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. A box of three individually pouched rings is NDC 78206-146-03. Generic appearance/package instructions should be separately checked.

The vaginal ring releases on average etonogestrel 0.120 mg/day and ethinyl estradiol 0.015 mg/day over three weeks. These daily release rates are not the total hormone contents and must not be reversed. The labeled cycle uses one disposable ring followed by a seven-day ring-free interval; implant, oral pill, and other ring products are different formulations.

Before dispensing, refrigerate at 2–8°C. After dispensing, storage is allowed for up to four months at 25°C, with excursions 15–30°C; avoid direct sunlight or temperatures above 30°C. The dispenser’s expiry is the earlier of four months after dispensing or the package expiry. Place a used ring in its reclosable foil sachet and discard in household waste inaccessible to children/pets; do not flush.